Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Vertebrobasilar Dolichoectasia
NCT07634120Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of sirolimus in vertebrobasilar dolichoectasia (VBD) (2 arms), sponsored by Huashan Hospital. Primary endpoints: Longitudinal changes of CAWE on 5T HR-VWI at 6 months, Longitudinal changes of SAWE on 5T HR-VWI at 6 months and 2 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
vertebrobasilar dolichoectasia (VBD)
Beyond the preview
Go deeper on NCT07634120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634120.